1. Phase II Study of High-Dose Somatostatin Analogue in Patients Either Previously Treated or Untreated Who Have Extensive-Stage Small Cell Lung Cancer
- Author
-
Robert F. Marschke, James B. Gerstner, Donald B. Wender, James A. Mailliard, Roscoe F. Morton, Chirantan Ghosh, James R. Jett, Ralph Levitt, Joseph P. Grill, and Jeff A. Sloan
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Antineoplastic Agents, Hormonal ,medicine.medical_treatment ,Phases of clinical research ,Anorexia ,Small-cell carcinoma ,Gastroenterology ,Internal medicine ,medicine ,Humans ,Carcinoma, Small Cell ,Survival analysis ,Aged ,Neoplasm Staging ,Chemotherapy ,business.industry ,Respiratory disease ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Somatostatin ,Oncology ,Toxicity ,Female ,medicine.symptom ,business - Abstract
The authors conducted a phase II study of somatostatin analogue in 18 patients with extensive stage small cell lung cancer (four with previous treatment, 14 without previous treatment). Patients received 2,000 mg subcutaneously thrice daily. They were required to have an Eastern Cooperative Oncology Group performance score of 0-2 and acceptable pretreatment biochemical parameters. No patient responded to treatment. The median time to progression was 44 days. The median survival was 106 days. Toxicity related to treatment consisted of mild diarrhea and anorexia. Somatostatin analogue is not active as a single agent in the treatment of extensive-stage small cell lung cancer.
- Published
- 1999
- Full Text
- View/download PDF